Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A open-label, randomized, crossover study evaluating relative bioavailability and dose linearity of five strengths of ruxolitinib extended release tablets in healthy adults patients

Next Previous
Trial Profile

A open-label, randomized, crossover study evaluating relative bioavailability and dose linearity of five strengths of ruxolitinib extended release tablets in healthy adults patients

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Acute myeloid leukaemia; Alopecia areata; Atopic dermatitis; Breast cancer; Breast disorders; Bronchiolitis obliterans; Cachexia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; COVID-19 pneumonia; Cytokine release syndrome; Essential thrombocythaemia; Graft-versus-host disease; Haematological malignancies; Head and neck cancer; Hodgkin's disease; Multiple myeloma; Myelodysplastic syndromes; Myelofibrosis; Polycythaemia vera; Precursor cell lymphoblastic leukaemia-lymphoma; SARS-CoV-2 acute respiratory disease; Thalassaemia; Vitiligo
  • Focus Adverse reactions; Pharmacokinetics

Most Recent Events

  • 08 Aug 2021 New trial record
  • 17 Jun 2021 Results presented at the 26th Congress of the European Haematology Association

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top